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Hereditary angioedema (HAE) is an autosomal dominant disease caused by C1-INH
deficiency due to mutations in SERPING1 (C1-INH-HAE) in most of the cases, or by
specific mutations in factor XII gene, F12 (F12-HAE). Identification of polymorphisms in
the genes encoding proteins from key pathways driving HAE can help to understand
how genetic diversity contributes to its phenotypic variability. Here, 15 genes related
to the Kallikrein-Kinin System (KKS) were analyzed by next generation sequencing in
59 patients with C1-INH-HAE or F12-HAE from Brazil, Denmark and Spain, and 19
healthy relatives in a total of 31 families. We identified 211 variants, from which 23
occurred only in Danish subjects and 79 were found only in Brazilian individuals, resulting
in 109/211 variations in common between European and Brazilian population in the
HAE families analyzed. BDKRB2 and CPM presented a large number of variants in
untranslated regions, 46/49 and 19/24, respectively; whereas ACE (n = 26), SERPING1
(n = 26), CPM (n = 24), and NOS3 (n = 16) genes presented the higher number of
variants directly affecting amino acid sequence. Despite the large amount of variants
identified, the lack of association between genotype and phenotype indicates that the
modulation of HAE symptom requires a more complex regulation, probably involving
pathways beyond the KKS, epigenetics and environmental factors. Considering the new
HAE types recently described, molecules involved in the regulation of vasculature and in
plasminogen activation become promising targets for future genetic studies.
Keywords: hereditary angioedema, Kallikrein-Kinin System, genetic variation, genotype-phenotype correlation,
C1 inhibitor deficiency, F12 mutation
INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal dominant disease caused by deleterious
mutations in SERPING1, leading to quantitative or functional C1-inhibitor deficiency
(C1-INH-HAE) (1). Less frequently, specific mutations in F12 gene (F12-HAE) can be detected in
patients with HAE with normal C1-inhibitor (2, 3). In addition, two new forms of HAE have been
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reported, HAE with mutations in angiopoietin-1 gene (ANGPT1)
(4) and HAE with mutations in plasminogen gene (PLG) (5).
A non-determined but substantial proportion of patients with
HAE and normal C1-inhibitor cannot be explained bymutational
findings at the moment and therefore is described as HAE of
unknown cause (U-HAE) (1, 6). C1-INH-HAE and F12-HAE
are related to the Kallikrein-Kinin System (KKS) activation
and augmented production of bradykinin (BK), leading to
vasodilation and angioedema episodes (1). In the KKS, factor
XII (encoded by F12 gene) activates plasma kallikrein (KK;
KLKB1 gene), which hydrolyzes highmolecular weight kininogen
(HMWK;KNG1 gene) releasing BK (7). BK binds the B2-receptor
(BDKRB2 gene) leading to endothelial nitric oxide synthase
activation (NOS3 gene). Carboxypeptidases N andM (genes CPN
and CPM) metabolize BK into des-Arg9-BK, which preferentially
activates B1-receptor (BDKRB1). Deleterious variations in genes
responsible for the control of BK release, as SERPING1, or its
metabolization, as CPN, CPM, angiotensin-converting enzyme
(ACE), and neprilysin (MME), are able to increase the amount of
BK released or its half-life, leading to or intensifying angioedema
episodes. Whereas, deleterious variations in F12, KLKB1, and
KNG1 could impair BK formation, working as a protective factor
in BK-mediated angioedema (7). Although a small phenotype
distinction can be noticed in HAE subtypes (2), there is a huge
variation in clinical characteristics even among carriers of the
same disease-causing mutation (1, 6).
A typical genome differs from the reference human genome
at 4.1–5.0 million sites with >99.9% being single nucleotide
polymorphisms and short indels (8). This large number of
variants can possibly be disease-causing or may contribute to
phenotypic variation and drug-response susceptibility. Indeed,
a cumulative effect of multiple polymorphisms may lead to
complex-trait genetic diseases (8). Here, we hypothesize that
variants in the KKS could explain the phenotypic variation
observed in HAE.
MATERIALS AND METHODS
Patients
Seventy-eight subjects analyzed by targeted next-generation
sequencing (NGS) belonged to 26 C1-INH-HAE families (45
mutation carriers, 15 healthy relatives) and 5 F12-HAE families
(14 mutation carriers, 4 healthy relatives) (Table 1). Additional
56 HAE patients were included in the study and had single
gene mutations sequenced by Sanger. Patients were previously
diagnosed by biochemical C1-INH and C4 measurements and
SERPING1 and/or F12 genotyping by Sanger sequencing.
This study was carried out in accordance with the
recommendations of ethical standards of the 1964 Declaration
of Helsinki with written informed consent from all subjects. The
Abbreviations: ACE, angiotensin-converting enzyme; C1-INH-HAE, hereditary
angioedema with C1 inhibitor deficiency; F12-HAE, hereditary angioedema with
mutation in F12 gene; HMWK, high molecular weight kininogen; KK, Plasma
Kallikrein; KKS, Kallikrein-Kinin System; U-HAE, hereditary angioedema of
unknown cause.
protocol was approved by the Ethics Committee in Research of
Universidade Federal de São Paulo (n◦56522).
Genetic Analysis
Since only a few possible genetic variants have been suggested
to be associated to the HAE phenotype (9–13), we explored 15
genes related to KKS in individuals from Brazil, Denmark, and
Spain, by NGS as previously described (14). Briefly, the targeted
genes (ACE, MME, KNG1, KLKB1, KLK1, F12, ENPEP, BDKRB1,
BDKRB2, NOS3, TAC1, CPN1, CPM, SERPING1, PRCP) were
amplified from patients’ DNA extracted from blood samples
by using Ion AmpliSeqTM Library Kit-2.0V (Life Technologies,
Carlsbad, CA, USA). NGS was performed with the Ion 316TM
Chip-v2 in Ion PGMTM Sequencer, which determined the amount
of sequence data analyzed. To guarantee a high-quality coverage
(minimum 20X) we limited the panel to the 15 selected genes,
in a total of 366 amplicons. Torrent Suit v3.2.1 and Ion
Reporter 4.0 (Life Technologies) were used to data analysis
and interpretation of variants. Probably pathogenic variants,
low coverage regions and SERPING1 and F12 coding regions
were validated by Sanger sequencing. Variants annotation was
performed using Ingenuity R© Variant Analysis (Qiagen) and
MetacoreTM (Thomson Reuters).
In addition to the 78 subjects evaluated by NGS, in 56 HAE
patients the exons 2 and 3 of BDKRB2 were also sequenced
by Sanger method (11 C1-INH-HAE and 45 U-HAE). U-HAE
patients were diagnosed according to Cicardi et al.’s guidelines
(1). Distribution of variants between groups was calculated by
Chi-square test.
All datasets generated and analyzed in this study are included
in the manuscript and the Supplementary Files (Tables S1, S2).
Clinical Characteristics
Patients were grouped and compared according to nationality
(Brazilian vs. European), HAE type (C1-INH-HAE vs. F12-HAE),
edema localization (face, extremities, abdominal pain, upper
respiratory tract, and genitals), mean frequency of attacks (per
year) and duration of episodes (days). Patients were categorized
in three groups according to the disease onset: (1) <12-
year-old, (2) from 12 to 25-year-old, and (3) >25-year-old.
Mean frequency and duration of swelling episodes data were
considered at baseline without prophylaxis or acute treatment.
The frequency of attacks was divided in low (<13 attacks per
year), medium (from 13 to 24), and high (>24). Patients were also
grouped according to the mean duration of swelling episodes in
short duration (<2 days), medium (2–3 days), and long duration
(>3 days). Distribution of variants was compared within the
selected groups.
RESULTS
NGS Analysis
In 26 C1-INH-HAE families, 23 mutations were considered
responsible for HAE, and all F12-HAE patients carried
p.Thr328Lys (Table 1). A total of 211 different variants were
identified in the 15 genes analyzed. Nine alterations occurred
in the 5′-UTR (4.3%) and 89 in the 3′-UTR (42.2%). Missense
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TABLE 1 | Families analyzed by NGS.
HAE type Fam ID Nat Mutation leading to HAE Mutation type N◦ symptomatic/
asymptomatic
Healthy relatives
(no mutation)
cDNA change Protein change
C1-INH-HAE 1 D c.-22-2A>G None Regulatory region 6/0 1
2 D c.23insT p.(Thr9fs) Frameshift 1/0 0
3 B c.51+1G>T ? Splicing defect 1/0 0
4 B c. 51+2T>C ? Splicing defect 2/0 0
5 B c.97_115del15 p.(Asp33fs) Frameshift 1/0 0
6 D c.143_144delCA p.(Thr48fs) Frameshift 2/0 0
7 D c.143_144delCA p.(Thr48fs) Frameshift 1/0 0
8 D c.143_144delCA p.(Thr48fs) Frameshift 1/0 0
9 B c.550G>C p.Gly184Arg Missense 1/0 0
10 D c.597C>G p.Tyr199Ter Nonsense 1/0 0
11 D c.668delA p.(Gln223fs) Frameshift 1/0 0
12 B c.752T>C p.Leu251Pro Missense 1/0 0
13 D c.762_763delCA p.(Asn254fs) Frameshift 2/0 0
14 D c.795G>A p.Trp265Ter Nonsense 1/0 0
15 D c.838_846del9 p.Ser280_Pro282del Inframe 1/0 0
16 D c.878T>C p.Ile293Thr Missense 1/0 0
17 B c.889G>A p.Ala297Thr Missense 2/0 0
18 D c.1029+4delA ? Splicing defect 1/0 0
19 B c.1104delA p.(Asp369fs) Frameshift 2/0 0
20 B c.1353_1354delGA p.(Glu451fs) Frameshift 1/0 1
21 B c.1369G>C p.Ala457Pro Missense 8/0 13
22 D c.1397G>A p.Arg466His Missense 1/0 0
23 D c.1417G>A p.Val473Met Missense 2/0 0
24 B c.1431C>A p.Phe477Leu Missense 1/0 0
25 B c.1480C>T p.Arg494Ter Nonsense 2/0 0
26 D c.1480C>T p.Arg494Ter Nonsense 1/0 0
F12-HAE 27 B c.983C>A p.Thr328Lys Missense 4/2 0
28 B c.983C>A p.Thr328Lys Missense 3/0 3
29 B c.983C>A p.Thr328Lys Missense 2/0 0
30 B c.983C>A p.Thr328Lys Missense 1/0 1
31 S c.983C>A p.Thr328Lys Missense 2/0 0
The mutations in SERPING1 and F12 identified as causative of HAE in each family are described. The number of symptomatic and asymptomatic mutation carriers, and healthy relatives
(without mutation) analyzed by NGS are shown in the last columns. B, Brazilian; D, Danish; Fam ID, family identification; Nat, nationality; S, Spanish; ?, not known.
mutations corresponded to 22.7% of the total, followed by
synonymous (21.8%), small insertions/deletions leading to
frameshift (3.8%), non-sense (1.9%), splice site (1.4%), and
intronic alterations (1.9%). A list containing all variants is found
in Table S1 (Supplementary Material). BDKRB2 presented the
highest number of variants (n = 49), followed by ACE (n = 26)
and SERPING1 (n = 26), and CPM (n = 24). The distribution
of variants per type or per gene was not significantly between
C1-INH-HAE and F12-HAE groups (Chi-square test with Yates’
correction). Considering only variants leading to change in
the structure of the protein (missense, nonsense, indels, and
predicted splicing sites), the genes in which more mutations
were found were SERPING1 (n = 23) and ACE (n = 10).
No probably damaging variants were identified in BDKRB1,
CPN/M, KNG1, KLK1, ENPEP, PRCP, or TAC1 genes. Few studies
suggest tissue kallikrein (KLK1 gene) may be involved in HAE
manifestations (15). Tissue kallikrein releases Lys-BK from low
molecular weight kininogen (also encoded by KNG1), which is
converted into BK by aminopeptidases (16) or into Lys-des-Arg9-
BK by carboxypeptidases.
BDKBR2 Variants
The change p.Arg14Cys in BDKRB2 was found 15 individuals,
and plGly354Glu in 16, without significant difference in
distribution among HAE subtypes (p = 0.1203 and p = 0.1900,
respectively, Chi-square test). The alterations p.Val376Met
(rs141958164) and p.Val208Ile (rs139203012) were found in one
U-HAE patient each.
Clinical Features and Phenotype-Genotype
Association
We found 23 mutations exclusively in Danish individuals and
79 only in Brazilians, resulting in 109/211 mutations in common
between European and Brazilian HAE families analyzed.
We compared the symptomatic patients regarding the
presence of facial swellings (43/57), swellings of extremities
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(41/57), abdominal swellings (45/57), upper airways (28/57), and
edema of the genitalia (21/57). The first attacks occurred before
the age of 12 in 26 patients (24 C1-INH-INH, 2 F12-HAE) (mean
= 6.7 years); between 12 and 25 years of age in 21 patients (20 C1-
INH-HAE, 5 F12-HAE) (mean= 17), and after 25 years of age in
eight (3 C1-INH-HAE, 5 F12-HAE) (mean = 33.8). Most of the
patients reported to experience up to 12 swelling episodes/year
without prophylaxis (31/47; mean = 4.6). Nine C1-INH-HAE
patients reported 13–24 attacks/year (mean = 19.8), and seven
reported more than 24 attacks/year (mean= 43.2).
Distribution of variants was compared within the selected
groups, but no specific mutation was significantly associated to
any of the clinical characteristic selected. However, five missense
mutations were classified as probably damaging by all in silico
predictive software (excluding SERPING1 variations) (Table 2).
DISCUSSION
HAE can be caused by C1-INH deficiency, in which more than
300 different mutations have already been considered responsible
for the disease (17). A smaller proportion of HAE patients present
specific mutations affecting a proline-rich region of factor XII
that leads to loss of glycosylation and enhanced autoactivation
mechanism of the zymogen activating the KKS (18). In spite
of the large mutational spectrum of SERPING1 in HAE, the
variation in the presentation of symptoms seems not to be
related to the type of the disease-causing mutation or even with
functional levels of C1-INH (19). Therefore, the search for new
genetic biomarkers could not only explain the variation in HAE
symptomatology, but also be used in diagnosis, prognosis, and
treatment response. Proteins of the KKS are strong candidates to
be regulating the severity and frequency of HAE attacks, since
they are directly involved in the BK-release pathway.
In this study, a large number of variants was found in a
regulatory portion of the 3′-untranslated BDKRB2 region (20).
Also, 40/78 individuals presented the 9 bp deletion in the exon 1
of BDKRB2, described to increase B2-receptor expression (21).
However, no correlation was found with these variants and
HAE clinical characteristics suggesting that the regulation of B2-
receptor expression through these regions is not strong enough
to modulate HAE attacks itself, in agreement with previous
data (22).
Variants classified as probably pathogenic in ACE
(p.Gly354Arg, p.Tyr244Cys, p.Thr916Met) were found in
Brazilian and Danish symptomatic patients, and p.Arg324Trp
was found only in one non-affected relative (family 21). Since
ACE degrades BK, deleterious alterations could increase BK half-
life, favoring longer edema episodes. It has been demonstrated
that ACE activity inversely correlates with severity scores
in F12-HAE (23); in contrast, C1-INH-HAE severity is not
depending on ACE, but highly depends on aminopeptidase
P activity (24). However, the C1-INH-HAE patients carrying
these mutations had distinguished clinical features from each
other (Table 2).
The mutation p.Cys548Tyr in KLKB1, found in two patients
from family 1 and one asymptomatic mutation carrier from
family 27 (F12-HAE), has been associated with KK deficiency
in a compound heterozygosity with the change p.Trp402Ter
(25). KK deficiency is a rare autosomal recessive condition
which causes an augmented activated partial thromboplastin
time, but no coagulation anomalies. Therefore, coexistence of
KK deficiency could attenuate or even abolish the symptoms
of HAE, since it is the key enzyme responsible for BK release.
The only missense mutation found together with p.Cys548Tyr
was the high frequent polymorphism p.Ser143Asn (66/78). This
polymorphismwas shown to cause KK deficiency with the change
p.Gly125Arg, both in homozygosity (26) and lying in the apple
domain 2 of the heavy chain of KK, through which kallikrein
interacts with HMWK domain 6 (27). However, p.Ser143Asn
was found in heterozygosity in the three patients carrying the
p.Cys548Tyr, discarding the hypothesis that this association
could be responsible by itself for the lack of symptoms observed
in the F12-HAE carrier. Furthermore, the Cys548 lies in the
catalytic domain of KK, far from the apple domain 2.
TABLE 2 | Probably pathogenic variants found in C1-INH-HAE and F12-HAE patients by NGS.
Gene Protein
change
Nat Patient/
family
Age
(years)
Onset
(years)
Frequency
(per year)
Duration
(days)
Face Extremities Abdominal Upper
airways
Genitalia
ACE p.G354R B 1/17 49 16 12 3 – × – × –
B 2/17 25 NI <1 <1 – – × – –
D 1/14 54 10 4 3 × × × × ×
p.Y244C D 6/1 73 15 <1 2–3 × × × – –
B 1/24 42 7 2 3 × × × × ×
p.T916M D 3/1 71 21 3 2–3 × × × – –
D 7/1 36 10 18 3 × × × × –
NOS3 p.D287N D 5/1 16 3 2 NI – – × – –
KLKB1 p.C548Y D 3/1 71 21 3 2–3 × × × – –
D 6/1 73 15 <1 2–3 × × × – –
B 4/27 51 Asympt. Asympt. Asympt. Asympt. Asympt. Asympt. Asympt. Asympt.
The mutations were analyzed as probably pathogenic when classified as damaging for all the in silico software assessed (SIFT, PolyPhen-2, PROVEAN, and CADD). Asympt,
asymptomatic; NI, not identified.
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Pathogenicity level of most of the new variants cannot be
confirmed only by in silico analysis (28). For example, the variant
p.Thr328Lys in F12 is responsible for most of F12-HAE cases (3,
18), but is classified as benign by many pathogenicity predictors.
Therefore, the discovery of new and rare variants possibly
involved in HAE pathogenesis requires not only experimental
evidences to assure the pathogenicity degree of each variant but
also the analysis of the overlap effect of different variations and
genes. Thus, despite the large number of variants identified in
KKS and related genes in this work, the small number of subjects
included and the lack of biochemical and functional analysis on
the variants are some limitations.
The studies of modulating factors in HAE must combine
the discovery of new mutations, genotype-phenotype association
including a large number of patients, and consider epigenetic and
environmental factors. To our knowledge, this is the largest study
exploring different genes in many HAE families. We expect that
the disclosure of the variants here presented in HAE patients and
the new recent findings in U-HAE will encourage further studies
correlating the KKS and the regulation of vasculature, as well as
larger international multicentric studies.
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Table S1 | Genetic variants found by NGS in HAE families. All the 211 variants
found in the 15 genes analyzed in the 78 subjects are listed in the table.
Pathogenicity prediction from SIFT (D, damaging; T, tolerated), PolyPhen-2 (B,
benign; P, possibly damaging; D, damaging), PROVEAN (D, damaging; N,
non-damaging) and CADD (threshold > 20) indicate the in silico analysis results.
†
Found only in Danish individuals.
Table S2 | Full dataset of genetic variants and clinical data. The sheet entitled
Genetic Variants contains all the variants found by NGS before validation and
patients filtering (raw data). Variants with the annotation ARTIFACT in the column
Functional Class correspond to the variations not confirmed by Sanger sequencing
validation and discarded in the final evaluation. The sheet Patients Raw contains
the chip and barcode identification, and clinical data from all the patients initially
sequenced, including U-HAE patients posteriorly excluded from NGS analysis.
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